PRICEFX
Pricefx , the global leader in cloud pricing software, today announced on stage at its user conference Accelerate19 that subscribers of the company’s core SaaS product offerings will now receive full access to the entire platform feature set for no additional cost. This is possible now that Pricefx has completed its evolution to a platform provider and unified its integration and connectivity capabilities. Pricefx’s powerful enterprise-grade technology platform provides simple point-and-click configuration for back-end, front-end, primary and third-party intellectual property (IP) enablement.
By including the platform with core product subscriptions, Pricefx will further lower the total cost of ownership for its customers. Additionally, the platform’s simple access to a broad range of pricing IP and ready-made capabilities will accelerate customer time-to-value on the Pricefx investment.
“The evolution from discrete solutions to a full-featured platform creates a new benchmark for best-in-class cloud pricing,” said Gabriel Smith, chief evangelist at Pricefx. “We are delivering powerful and innovative new features that create a more connected, integrated and modular cloud-native platform -- and at no additional charge to customers. Organizations can now harness unprecedented power of the full Pricefx product suite delivered through an enterprise-scale platform that manages data, multi-system connectivity, and more, with the same fast, flexible and friendly SaaS approach the industry has come to expect from Pricefx.”
Previously, Pricefx offered IntegrationManager as separate product which connected Pricefx SaaS products with back-end data and services such as ERP and PLM systems. Pricefx also continued to build front-end systems integrations with leading providers and helped its partners develop focused and pricing-specific IP. Today, these capabilities have been unified inside a single platform free to customers of the company’s core SaaS products and to partners for the development, addition and distribution of its own IP.
The Pricefx platform will continue to provide and support all of the back-end connectivity and capabilities of IntegrationManager and will continue enabling connectivity with leading CRM systems and across the Pricefx suite of products. Now customers can more easily integrate Pricefx into their organization and leverage the full power of the platform.
The platform will now also enable customers to easily select and configure specific ready-made pricing IP – algorithms, data sets, guidance, templates, models and starter kits. Customers will be able to quickly establish connectivity to and distribute IP across their existing instance of Pricefx. Additional platform features include access to foundational services including master data management (MDM), workflow and dashboard capabilities.
Follow Pricefx
Blog: https://www.pricefx.com/site/blog/
Twitter: https://twitter.com/price_fx
LinkedIn: https://www.linkedin.com/company/price-f-x-/
About Pricefx
Established in 2011 in Germany, Pricefx is the global leader in SaaS pricing software, offering a comprehensive suite of solutions that are fast to implement, easy to use, and flexibly adapt to any business need. Pricefx delivers a complete price optimization and management platform based on native cloud architecture, to power pricing Insights, Definitions, and Realization. Their innovative solution works for both B2B and B2C enterprises of any size, in any industry, in any part of the world. Pricefx’s business model is entirely based on the satisfaction and loyalty of its customers. Today, Pricefx delivers Passion for Pricing to more than 100 customers in more than 37 countries worldwide. For more information, please visit www.pricefx.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190515005046/en/
Contact:
Media Contact: Cathy Summers Summers PR cathy@summers-pr.com +1 (415) 483-0840
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Positive Phase 3 Results Support ZIIHERA® as HER2-Targeted Therapy-of-Choice and Combination with TEVIMBRA® and Chemotherapy as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma17.11.2025 12:00:00 CET | Press release
ZIIHERAplus TEVIMBRA and chemotherapy demonstrated clinically meaningful and statistically significant improvements in PFS and OS versus trastuzumab and chemotherapyZIIHERA plus chemotherapy showed a clinically meaningful and statistically significant improvement in PFS versus trastuzumab and chemotherapy, and a clinically meaningful effect with a strong trend toward statistical significance for OS at the first interim analysisFirst Phase 3 trial in 15 years to demonstrate a clinical benefit in this patient population with a novel HER2-targeted therapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive top-line results from the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), a HER2-targeted bispecific antibody, in combination with chemotherapy, with or without PD-1 inhibitor TEVIMBRA® (tislelizumab), as first-line treatment for HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcin
BoConcept, Lego, Lurpak, and Pandora are among the Honoured Winners of the 2025-2026 World Branding Awards in Osaka17.11.2025 11:48:00 CET | Press release
The 20th World Branding Awards celebrated the success and achievements of leading brands across National, Regional, and Global categories. In the 2025–2026 edition, over 1,092 brands from 66 countries were nominated as “Brand of the Year”. From this distinguished selection, fewer than 100 brands emerged as winners, representing the highest standards of excellence across the three tiers of recognition. The World Branding Awards Ceremony stepped outside London for the first time, bringing its global presence to the Osaka City Museum of Fine Arts. Over 80 international guests joined the celebration, hosted by Allie Sakakibara and enriched by a keynote from Miho Noguchi on immersive brand experiences. Honoured as Global winners in branding across diverse industries were Cadbury (USA), IKEA (Sweden), Marriott International (United Kingdom), Nike (USA), Sennheiser (Germany), and Yakult (Japan). Winners from Denmark include BoConcept, Lego, Lurpak, and Pandora.Other National tier winners incl
Global Winners of the 2025–2026 World Branding Awards Announced at First-Ever Japan Ceremony17.11.2025 11:43:00 CET | Press release
Now in its 20th edition, the World Branding Awards continues to spotlight the world’s most impactful and trusted brands. This year, over 1,092 brands from 66 countries were nominated as “Brand of the Year”, with less than 100 declared Winners across Global, Regional, and National tiers. The World Branding Awards Ceremony stepped outside London for the first time, bringing its global presence to the Osaka City Museum of Fine Arts. The 2025–2026 edition welcomed over 80 international guests and was presented by the acclaimed Allie Sakakibara. The evening was further elevated by a keynote presentation from Miho Noguchi, who shared insights on building emotional resonance through immersive brand experiences. Global Tier winners celebrated their outstanding branding excellence across various industries, including IKEA (Sweden), Lurpak (Denmark), Marriott International (United Kingdom), Nike (USA), Sennheiser (Germany), and Yakult (Japan). These brands consistently demonstrated strength, inf
Henlius and Organon Announce US FDA Approval of POHERDY® (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the US17.11.2025 11:30:00 CET | Press release
Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced that the US Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for POHERDY® (pertuzumab-dpzb) 420 mg/14 mL injection for intravenous use, an interchangeable biosimilar to PERJETA (pertuzumab), for all indications of the reference product.1 POHERDY is the first and only approved pertuzumab biosimilar in the US, representing an important milestone in expanding access to quality and potentially more affordable biologic therapies for patients with certain HER2-positive breast cancers.2 "Expanding access to treatments for diseases that disproportionately impact women, including breast cancer, the most common cancer among women in the US excluding skin cancer, is at the core of our mission,” said Jon Martin, US Commercial Lead, Biosimilars and Established Brands at Organon.3 “Not only is POHERDY the first approved biosimilar to PERJETA in the US, but its approval also builds
WEX® Unlocks Access to 20,000+ Tesla Superchargers Across Europe17.11.2025 11:15:00 CET | Press release
EV drivers of any car brand using the EV Driver by WEX app can now charge at one of Europe’s largest and most reliable charging networks, benefitting from low-cost fast charging across 1,500+ locations. WEX® (NYSE: WEX), the global commerce platform that simplifies the business of running a business, today announced integration with the Tesla Supercharger network, adding over 20,000 fast-charging points across 1,500+ locations to its platform. The move significantly expands charging options for WEX’s customers, particularly in areas where high-power charging has been limited or expensive. By bringing Tesla Superchargers into their ecosystem, WEX gives drivers access to competitively priced fast charging with speeds up to 250 kW, increasing availability of high-power charging stations by 10%. WEX customers already use the EV Driver by WEX app to charge at over 1 million charging points throughout Europe. Now, they can access Tesla Superchargers with the same seamless experience: compari
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom